BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23473919)

  • 21. Intracellular dCTP/ara-CTP ratio and the cytotoxic effect of ara-C.
    Kawasaki H; Kuwabara H; Hori H; Higashigawa M; Ohkubo T; Sakurai M
    Cancer Invest; 1991; 9(4):409-13. PubMed ID: 1884247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical modulation of cytarabine triphosphate by clofarabine.
    Cooper T; Ayres M; Nowak B; Gandhi V
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):361-368. PubMed ID: 15723262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formation of cytosine arabinoside-5'-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity.
    Köhl U; Schwabe D; Montag E; Bauer S; Mieth B; Cinatl J; Cinatl J; Rohrbach E; Mainke M; Weissflog A
    Eur J Cancer; 1995; 31A(2):209-14. PubMed ID: 7718327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
    Ossenkoppele GJ; Graveland WJ; Sonneveld P; Daenen SM; Biesma DH; Verdonck LF; Schaafsma MR; Westveer PH; Peters GJ; Noordhuis P; Muus P; Selleslag D; van der Holt B; Delforge M; Löwenberg B; Verhoef GE;
    Blood; 2004 Apr; 103(8):2908-13. PubMed ID: 15070662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of arabinosyl nucleotides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Biochem Pharmacol; 1989 Oct; 38(20):3551-8. PubMed ID: 2479383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
    Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
    Hubeek I; Litvinova E; Peters GJ; Broekhuizen R; Haarman EG; Huismans DR; Cloos J; Zwaan CM; Fleischhack G; Creutzig U; Kaspers GJ
    Int J Oncol; 2004 Dec; 25(6):1823-9. PubMed ID: 15547723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and application of a rapid and sensitive liquid chromatography-mass spectrometry method for simultaneous analysis of cytarabine, cytarabine monophosphate, cytarabine diphosphate and cytarabine triphosphate in the cytosol and nucleus.
    Huang S; Liu L; Liu X; Song L; Huang C; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114582. PubMed ID: 35101802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
    Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
    Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced production of intracellular ara-CTP after sequential use of methotrexate and 1-beta-D-arabinofuranosylcytosine.
    Nobori T; Okubo T; Shimizu N; Kawasaki H; Sako T; Komada M; Hirota H; Kamiya H; Sakurai M
    Leuk Res; 1985; 9(10):1263-5. PubMed ID: 4068748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
    Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
    Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
    Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
    Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
    Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
    Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.